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and hearing loss (40.5 vs. 22.5%, P = 0.010) was observed 
in patients treated by IMRT.
Conclusion IMRT provides better locoregional relapse-
free survival and overall survival, especially in late-stage 
children and adolescent NPC patients, and is associated 
with a lower incidence of Grade 2–4 xerostomia as well as 
hearing loss compared with 2D-CRT. Distant metastasis 
remains a challenge in the treatment of children and ado-
lescent NPC.
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Abstract 
Purpose To compare the clinical outcomes and toxicities 
of two-dimensional conventional radiotherapy (2D-CRT) 
and intensity-modulated radiotherapy (IMRT) for the treat-
ment of children and adolescent nasopharyngeal carcinoma 
(NPC).
Methods A total of 176 children with non-metastatic NPC 
treated at Sun Yat-sen University Cancer Center between 
October 2003 and September 2013 were included in this 
study. Of the 176 patients, 74 received 2D-CRT and 102 
were treated with IMRT. The clinical outcomes and acute 
and late toxicities were determined and compared.
Results The IMRT group achieved significantly higher 
overall survival (OS) (90.4% vs. 76.1% at 5 year, P = 0.007) 
and disease-free survival (DFS) (85.7% vs. 71.2%, 
P = 0.029) mainly due to an improvement in locoregional 
relapse-free survival (LRRFS) (97.9 vs. 88.3%, P = 0.049). 
After stratification by disease stage, IMRT provided signifi-
cant benefits for patients with stage III–IV disease in terms 
of OS, LRRFS and DFS. Multivariate analyses indicated 
that the treatment group (2D-CRT vs. IMRT) was a prog-
nostic factor for OS, LRRFS and DFS. A significant reduc-
tion in Grade 2–4 xerostomia (52.7 vs. 34.3%, P = 0.015) 
Wen-Ze Qiu and Xing-Si Peng contributed equally to this study.
 * Ka-Jia Cao 
 caokajia@163.com
1 Department of Nasopharyngeal Carcinoma, Sun Yat-
sen University Cancer Center, Guangzhou 510060, 
People’s Republic of China
2 Collaborative Innovation Center for Cancer Medicine, State 
Key Laboratory of Oncology in South China, Guangzhou, 
People’s Republic of China
 J Cancer Res Clin Oncol
1 3
CCT  Concurrent chemotherapy
WHO  World Health Organization
Background
Nasopharyngeal carcinoma (NPC) is endemic in South-
east Asian countries, where the incidence rates range 
from 30 to 50 in 100,000 people. NPC is strongly asso-
ciated with Chinese ethnic origin (Wei and Sham 2005; 
Wei et  al. 2014). In most other populations, the disease 
is rare, with an intermediate incidence in Mediterranean 
basin countries and Greenland (Wei and Sham 2005). 
One remarkable difference between Mediterranean and 
Asian NPCs is the age distribution. Although a unimodal 
peak at 50–60 years exists among endemic countries, an 
additional minor early peak appears at 10–20 years of age 
among Mediterranean countries (Ayan et al. 2003). NPC 
in children differs from that of their adult counterparts 
in its close association with Epstein–Barr virus (EBV) 
infection, its undifferentiated histology, and the high inci-
dence of locoregionally advanced disease (Ayan et  al. 
2003; Young and Dawson 2014).
The optimal treatment modality in children has not 
been established to date. The treatment recommendations 
for childhood NPC typically follow guidelines estab-
lished for adults. Previous studies have reported that in 
paediatric and adolescent NPC patients treated with two-
dimensional conventional radiotherapy (2D-CRT), the 
5-year overall survival rate varied from 55 to 80%, with 
an incidence of late sequelae of 65–85% (Wolden et  al. 
2000; Hu et al. 2013).
Intensity-modulated radiotherapy (IMRT) is an inno-
vative modality with the overall goal of providing a 
high dose of radiation to the tumour bed to achieve local 
control while attempting to spare the critical surround-
ing structures from high-dose radiation damage (Kwong 
et  al. 2004). According to experiences with the use of 
IMRT for adults with NPC (Peng et al. 2012; Mao et al. 
2015), it is expected that implementation of IMRT for 
children and adolescent NPC would also translate into an 
improved outcome with reduced treatment-related tox-
icities. However, studies that examine the application of 
IMRT in children and adolescent NPC are rare (Laskar 
et al. 2008; Guo et al. 2015), and no evidence has dem-
onstrated significant advantages of IMRT compared with 
2D-CRT regarding the survival rate and late treatment-
related toxicities. The purpose of this retrospective study 
is to assess whether the use of IMRT is associated with 
improved clinical outcomes and reduced treatment-




A total of 176 children with NPC were treated at the Sun 
Yat-sen University Cancer Center from October 2003 to 
September 2013. Patients were 7–20 years of age and his-
tologically diagnosed with untreated non-metastatic NPC. 
Of the 176 patients, 129 were boys and 47 were girls (male/
female ratio, 2.74:1). Most patients (69, 39.2%) presented 
with cervical lymphadenopathy. Other common present-
ing symptoms included epistaxis (35, 19.9%), tinnitus (28, 
15.9%), headache (21, 11.9%), nasal obstruction or dis-
charge (20, 11.4%), trismus (2, 1.1%) and facial numbness 
(1, 0.6%). Pretreatment evaluations included a complete 
history and physical examination, endoscopy and biopsy, 
complete blood count determination, liver and renal func-
tion tests, chest X-ray, and computed tomography (CT) or 
magnetic resonance imaging (MRI) of the head-and-neck 
region. CT scans of the abdominopelvis or chest, bone 
scans, and positron emission tomography scans were per-
formed when clinically indicated. Patients underwent clini-
cal staging according to the American Joint Committee on 
Cancer staging system (seventh edition). The medical eth-
ics committee of Sun Yat-Sen University Cancer Center 
approved the study. All patients were treated under the 
principles of the Helsinki declaration.
Treatment methods
2D‑CRT
The details of the 2D-CRT techniques utilized in our cancer 
centre were previously reported (Lai et al. 2011). Patients 
were immobilized in the supine position with a thermoplas-
tic mask and treated with two lateral opposing faciocervi-
cal portals to irradiate the nasopharynx and upper neck in 
one volume followed by application of the shrinking-field 
technique to limit irradiation of the spinal cord. An anterior 
cervical field was used to treat the neck with a laryngeal 
block. The accumulated radiation doses were 66–80  Gy 
(median, 70 Gy), with 2 Gy per fraction applied to the pri-
mary tumour, 60–64  Gy applied to the involved areas of 
the neck, and 50  Gy applied to the uninvolved areas. All 
patients were treated with one fraction daily for 5 days per 
week.
A boost portal was performed if necessary. Differ-
ent radiation energies, including megavoltage photons 
(6 or 8 MV) and electrons, were used. A boost dose (8 to 
12 Gy per 4–6 fractions) was delivered to the skull base in 
patients with NPC involving the skull base and intracranial 
extension.
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IMRT
The IMRT technique has also been described previ-
ously (Zhang et al. 2015). All patients were immobilized 
in the supine position with a head, neck, and shoulder 
thermoplastic mask. Two sets of images with and with-
out contrast were obtained from the computed tomogra-
phy (CT) simulator for treatment planning. All patients 
were scanned with serial 3-mm slices from the vertex 
through the clavicles. The gross tumour volumes of the 
nasopharynx (GTVnx) and positive neck lymph nodes 
(GTVnd) were delineated according to our previously 
described institutional treatment protocol (Zhao et  al. 
2004), which is in agreement with the International Com-
mission on Radiation Units and Measurements Reports 
50 and 62. The first clinical tumour volume (CTV1) 
was defined as the GTVnx plus a margin of 5–10  mm 
for potential microscopic spread, including the entire 
nasopharyngeal mucosa plus a 5-mm submucosal vol-
ume. The second CTV (CTV2) was defined by adding a 
margin of 5–10  mm to CTV1 and included the follow-
ing regions, which required prophylactic irradiation: the 
retropharyngeal lymphnode regions, clivus, skull base, 
pterygoid fossae, parapharyngeal space, inferior sphe-
noid sinus, posterior edge of the nasal cavity, maxillary 
sinuses, and lymphatic drainage area. The planning target 
volume (PTV) for GTVs and CTVs were generated auto-
matically by adding a 5-mm margin after delineation of 
tumour targets according to the immobilization and local-
ization uncertainties. The prescribed dose was 62–70Gy 
(median, 68  Gy) to the PTV of the GTVnx (PTVnx), 
58–66 Gy to the PTV of the GTVnd (PTVnd), 56–64 Gy 
to the PTV of the CTV1 (PTV1), and 50–58  Gy to the 
PTV of the CTV2 (PTV2) in 28–33 fractions. All patients 
were treated with one fraction daily over 5 days per week. 
The doses limited to the major organs at risk were as fol-
lows: the brain stem, with a 3-mm margin, Dmax < 54 Gy; 
spinal cord, with a 5-mm margin, Dmax < 40  Gy; the 
optic nerve, chiasm and temporal lobe, Dmax < 54 Gy; the 
parotid gland, V30–35 < 50%.
Chemotherapy
In total, 166 (94.3%) patients received chemotherapy, with 
126 and 117 patients treated by neoadjuvant and concurrent 
chemotherapy, respectively. Neoadjuvant chemotherapy 
consisted of a cisplatin and 5-fluorouracil (5-FU)-based 
regimen (PF regimen) every 3 weeks for 1–3 cycles. In 
concurrent chemotherapy, 23 patients received a 30 mg/m2/
week cisplatin regimen (median cycles: 5) and 94 patients 
received 80 to 100 mg/m2/q3w cisplatin regimen (median 
cycles: 2).
Follow‑up
Patients received follow-up every 3  months for the first 
3 years after RT, every 6 months for years 3–5 and annually 
thereafter. Follow-up included physical examinations, chest 
X-ray, abdominal ultrasonography, MRI of the head and 
neck and/or bone scan. Late therapy-related complications 
were scored according to the Common Toxicity Criteria 
(CTC) version 3.0 of the U.S. National Institutes of Health. 
The last follow-up date was December 31, 2015.
Statistical analysis
The following endpoints were assessed: overall survival 
(OS), locoregional relapse-free survival (LRRFS), distant 
metastasis-free survival (DMFS), and disease-free survival 
(DFS). OS was defined as the time from the start of RT to 
death by any cause. LRRFS was defined as the time from 
the start of RT to the first occurrence of local or regional 
recurrence. DMFS was defined as the time from the start 
of RT to the first occurrence of distant metastasis. DFS was 
defined as the time from the start of RT to the first occur-
rence of local or regional recurrence or distant metasta-
sis. Pearson’s χ2 tests were used to explore the differences 
between categorical variables. The actuarial rates were 
generated according to the methods of Kaplan and Meier. 
Differences between survival curves were compared using 
the log-rank test. Multivariate analysis was conducted by 
the Cox proportional hazard regression model. A P value 
of less than 0.05 was considered significant. Statistical 




The characteristics of patients in the IMRT group and 
2D-CRTgroup are presented in Table  1. A total of 102 
patients received IMRT, and 74 received 2D-CRT. The 
groups were comparable with respect to the host factors, 
pathologic type, disease stage, and the use of chemotherapy 
(all, P > 0.05). The median follow-up time was 52 months 
(range 3–136 months).
Patterns of treatment failure
Thirty-four patients (19.3%) failed during follow-up, 
including nine in locoregional relapse, 23 in distant metas-
tasis and two in both (Table 2). The median failure times 
were 13 months (3–86 months) and 14 months (3–77 
months) for locoregional relapse and distant metastasis, 
 J Cancer Res Clin Oncol
1 3
respectively. At the latest follow-up, 18 patients in the 
2D-CRT group and 6 in the IMRT group died. The cause of 
death was related to recurrent cancer in 17 patients (94.4%) 




Figure  1a shows OS curves for patients in both study 
groups. At 5 years, the OS rates were 76.1% for the 
2D-CRT group and 90.4% for the IMRT group. The differ-
ence was statistically significant [Hazard Ratio (HR): 0.30; 
95% confidence interval (CI): 0.12–0.78; P = 0.007]. After 
stratification for the overall stage, the 5-year OS for stage 
III–IV disease for the IMRT group was increased compared 
to that of the 2D-CRT group (P = 0.011). After stratifi-
cation for the T stage and N stage, the OS at 5 years was 
significantly greater for the IMRT group for patients with 
T3–4 or N2–3 disease (P = 0.021, P = 0.025, respectively).
LRRFS
Figure  1b presents the LRRFS curves for the patients in 
both study groups. A significant difference in LRRFS 
was observed between the groups (HR: 0.28; 95% CI: 
0.07–0.98; P = 0.049). The LRRFS rates at 5 years were 
88.3% in the 2D-CRT group and 97.9% in the IMRT group. 
The results of stratification for the overall stage revealed a 
borderline significant difference in LRRFS, favouring treat-
ment with IMRT in patients with stage III–IV disease (HR: 
0.29; 95% CI: 0.08–1.10; P = 0.052). After stratification for 
the T stage and N stage, no significant difference in LRRFS 
was observed between the groups.
DMFS
Figure  1c shows the DMFS curves for the study groups. 
There was no significant difference between the groups 
(HR: 0.61; 95% CI: 0.27–1.34; P = 0.211). The 5-year 
DMFS rates were 80.1% in the 2D-CRT group and 86.6% 
in the IMRT group. After stratification for the overall stage, 
T stage and N stage, no significant difference in DMFS was 
observed between the groups.
DFS
Figure  1d shows DFS curves for patients in both study 
groups. At 5  years, the DFS rates were 71.2% for the 
2D-CRT group and 85.7% for the IMRT group. This dif-
ference was statistically significant (HR: 0.47; 95% CI: 
0.23–0.94; P = 0.029). After stratification for the overall 
Table 1  Characteristics of the 176 patients with paediatric and ado-
lescent nasopharyngeal carcinoma
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-
modulated radiotherapy, NAC neoadjuvant chemotherapy, CCT con-
current chemotherapy
Characteristics 2D-CRT (%, n = 74) IMRT (%, n = 102) P
Gender 0.793
 Male 55 (74.3) 74 (72.5)
 Female 19 (25.7) 28 (27.5)
Age (years) 0.190
 ≤14 14 (18.9) 28 (27.5)
 >14 60 (81.1) 74 (72.5)
Pathologic type 0.369
 WHO II 0 (0) 3 (2.9)
 WHO III 74 (100.0) 99 (97.1)
T stage 0.989
 T1 2 (2.7) 3 (2.9)
 T2 2 (2.7) 7 (6.9)
 T3 37 (50.0) 44 (43.1)
 T4 33 (44.6) 48 (47.1)
N stage 0.861
 N0 5 (6.8) 6 (5.9)
 N1 21 (28.4) 29 (28.4)
 N2 31 (41.9) 48 (47.1)
 N3 17 (23.0) 19 (18.6)
Overall stage 0.823
 I 1 (1.4) 1 (1.0)
 II 1 (1.4) 4 (3.9)
 III 32 (43.2) 39 (38.2)





 No 7 (9.5) 3 (2.9)
 NAC 33 (44.6) 16 (15.7)
 CCT 15 (20.3) 25 (24.5)
 NAC + CCT 19 (25.7) 58 (56.9)
Table 2  Patterns of disease failure in patients treated with 2D-CRT 
vs. IMRT
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-
modulated radiotherapy
Failure pattern 2D-CRT [cases (%)] IMRT [cases (%)] P
Locoregional only 7 (9.5) 2 (2.0) 0.060
Distant metastasis 
only
13 (17.6) 10 (9.8) 0.131
Both locoregional 
relapse and distant 
metastasis
1 (1.4) 1 (1.0) 1.000
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stage and N stage, the DFS at 5  years was significantly 
greater for the IMRT group for patients with stage III–IV 
or N2–3 disease (P = 0.037, P = 0.034, respectively). After 
stratification for the T stage, no significant difference in 
DFS was observed between the groups.
Prognostic factors
The value of various potential prognostic factors on pre-
dicting OS, LRRFS, DMFS, and DFS was evaluated. Uni-
variate analysis by log-rank test showed that the N stage 
and treatment group were significantly associated with 
OS. The treatment group was significantly associated with 
LRRFS. Age, T stage, N stage, and overall stage were sig-
nificantly related to DMFS. The T stage, N stage, overall 
stage and treatment group were significantly related to DFS 
(Table 3).
Multivariate analysis by Cox proportional-hazards 
model revealed that the T stage, N stage, overall stage and 
treatment group were independent prognostic predictors 
of OS (P = 0.017, P < 0.001, P = 0.031, P = 0.007, respec-
tively). The treatment group was the only independent 
prognostic predictor of LRRFS (P = 0.041). The T stage 
and N stage were independent prognostic predictors of 
DMFS (P = 0.012, P < 0.001, respectively). The T stage, 
N stage and treatment group were independent prognostic 
predictors of DFS (P = 0.005, P < 0.001, P = 0.031, respec-
tively) (Table 4).
Acute and late toxicities
No significant differences in acute Grade 3–4 toxicities 
were observed between the two groups (Table  5). With 
respect to late complications, the rates of Grade 2–4 xeros-
tomia and hearing loss were significantly greater in the 
2D-CRT group compared with the IMRT group (Table 6). 
Of note, one patient in the 2D-CRT group died of severe 
radiation encephalopathy after 88 months.
Discussion
IMRT is an ideal radiation modality for NPC given its 
potential for excellent target coverage and normal tissue 
sparing. Several published meta-analyses are encourag-
ing, demonstrating that IMRT not only improves locore-
gional control and survival but also reduces acute and late 
toxicities (Penagaricano and Papanikolaou 2003, 2012). 
Fig. 1  Comparisons of the overall survival (a), locoregional relapse-
free survival (b), distant metastasis-free survival (c) and disease-free 
survival (d) for children and adolescent nasopharyngeal carcinoma 
(NPC) treated by two-dimensional conventional radiotherapy (2D-
CRT) versus intensity-modulated radiotherapy (IMRT)
 J Cancer Res Clin Oncol
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Table 3  Univariate analysis of 
prognostic factors for paediatric 
and adolescent nasopharyngeal 
carcinoma
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy, OS overall 
survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-
free survival
Variate 5-year survival rate (%)
OS P LRRFS P DMFS P DFS P
Gender 0.535 0.533 0.436 0.403
 Male 81.5 93.2 82.2 77.7
 Female 89.9 95.3 87.5 83.2
Age 0.886 0.292 0.023 0.243
 ≤14 88.0 89.1 97.6 86.7
 >14 82.7 95.2 79.9 77.2
T stage 0.166 0.192 0.004 0.004
 T1–3 88.5 95.6 90.8 86.7
 T4 78.1 91.6 75.4 70.6
N stage <0.001 0.079 <0.001 <0.001
 N0–2 88.8 95.2 88.8 84.4
 N3 62.3 87.6 61.8 57.8
Overall stage 0.212 0.197 0.022 0.015
 Stage I–III 85.4 96.0 90.2 86.4
 Stage IV 79.7 92.0 78.4 73.5
Treatment group 0.007 0.049 0.211 0.029
 2D-CRT 76.1 88.3 80.1 71.2
 IMRT 90.4 97.9 86.6 85.7
Chemotherapy 0.492 0.356 0.167 0.102
 No 100 100 100 100
 Yes 82.5 93.4 82.5 77.9
Neoadjuvant chemotherapy 0.686 0.532 0.955 0.590
 No 83.1 95.0 83.2 80.2
 Yes 84.2 90.9 85.3 77.1
Concurrent chemotherapy 0.472 0.748 0.507 0.338
 No 85.3 94.6 84.4 80.1
 Yes 78.4 94.8 81.1 76.4
Table 4  Multivariate analysis of prognostic factors for paediatric and adolescent nasopharyngeal carcinoma
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy, OS overall survival, LRRFS locoregional relapse-
free survival, DMFS distant metastasis-free survival, DFS disease-free survival
Variate OS LRRFS DMFS DFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gender
Male vs. female 1.12 (0.40–3.15) 0.834 0.88 (0.18–4.22) 0.868 0.94 (0.34–2.58) 0.901 0.97 (0.41–2.28) 0.942
Age
 ≤14 vs. >14 0.61 (0.22–1.72) 0.348 0.38 (0.10–1.36) 0.135 5.55 (0.74–41.49) 0.095 1.33 (0.50–3.50) 0.568
T stage
 T1-3 vs. T4 6.66 (1.40–31.70) 0.017 3.53 (0.35–35.35) 0.284 14.14 (1.81-110.62) 0.012 8.63 (1.91–39.09) 0.005
N stage
 N0-2 vs. N3 11.94 (3.75–37.98) <0.001 4.37 (0.89–21.38) 0.069 7.84 (2.97–20.64) <0.001 6.41 (2.74–15.02) <0.001
Overall stage
 I–III vs. IV 0.12 (0.02–0.83) 0.031 0.47 (0.03–7.36) 0.591 0.11 (0.01–1.15) 0.066 0.19 (0.03–1.09) 0.062
Treatment group
 2D-CRT vs. IMRT 0.27 (0.10–0.69) 0.007 0.24 (0.06–0.94) 0.041 0.65 (0.29–1.46) 0.299 0.46 (0.23–0.93) 0.031
J Cancer Res Clin Oncol 
1 3
However, because children and adolescents with NPC who 
meet the strict selection criteria accounted for only a small 
part of these studies, the real role of IMRT in this popu-
lation remains unclear. Our current study aimed to assess 
whether the use of IMRT is associated with improved clini-
cal outcomes and reduced treatment-related toxicities com-
pared with 2D-CRT in children and adolescent NPC.
The results of this retrospective study comparing 
2D-CRT with IMRT for the treatment of children and 
adolescent NPC showed that IMRT was associated with 
improved locoregional control and overall survival, espe-
cially for late-stage, non-metastatic disease, and a lower 
incidence of late toxicities.
In our study, improvement of locoregional control in the 
IMRT group for stage I/II patients was not remarkable. We 
hypothesize that the reason for this may be that 2D-CRT 
provides excellent locoregional control in early-stage NPC 
patients. However, the sample size of stage I/II (2 patients 
for 2D-CRT group and 5 for IMRT group) is insufficient 
to be statistically representative. Our results showed that 
the locoregional control rate was marginally significantly 
greater for non-metastatic stage III, and stage IVa and IVb 
patients in the IMRT group compared with the 2D-CRT 
group (P = 0.052). The tumour may extend close to the 
adjacent critical structures in patients with locoregionally 
advanced NPC, and the 2D-CRT dose and coverage often 
have to be compromised to avoid unacceptable complica-
tions, resulting in poor disease control. The aim of treat-
ment for locoregionally advanced disease is to improve 
locoregional control by escalating the radiation dose in 
the tumour without exceeding the tolerance of the adjacent 
critical structures. IMRT can deliver a higher total dose and 
dose per fraction to the target volume and maintain low 
doses to the adjacent critical structures (Laskar et al. 2008). 
A prospective, randomized study by Peng et al. compared 
the outcomes and toxicities of IMRT vs. 2D-CRT for the 
treatment of NPC, and the result showed that better local 
recurrence-free survival and a lower incidence of toxici-
ties can be achieved in the IMRT group for late-stage NPC 
patients (Peng et  al. 2012). In the current study, the NPC 
failure pattern was not altered by IMRT, and distant metas-
tasis remained the major pattern of failure in paediatric and 
adolescent NPC, a result similar to the findings of other 
reports (Tao et  al. 2013; Guo et  al. 2015). The relatively 
short time to systemic failure in the absence of locore-
gional failure might suggest that subclinical metastasis 
Table 5  Acute Grade 3–4 
toxicities in patients treated 
with 2D-CRT versus IMRT
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy
Acute toxicity 2D-CRT (n = 74, %) IMRT (n = 102, %) P
Grade 3 Grade 4 All Grade 3 Grade 4 All
Leucopenia 4 (5.4) 1 (1.4) 5 (6.8) 13 (12.7) 0 13 (12.7) 0.196
Neutropenia 5 (6.8) 1 (1.4) 6 (8.2) 11 (10.8) 5 (4.9) 16 (15.8) 0.133
Anaemia 2 (2.7) 0 2 (2.7) 2 (2.0) 0 2 (2.0) 1.000
Thrombocytopenia 0 1 (1.4) 1 (1.4) 3 (2.9) 0 3 (2.9) 0.640
Hepatotoxicity 1 (1.4) 0 1 (1.4) 0 0 0 0.420
Nephrotoxicity 1 (1.4) 0 1 (1.4) 1 (1.0) 1 (1.0) 2 (2.0) 1.000
Dermatitis 6 (8.1) 0 6 (8.1) 3 (2.9) 0 3 (2.9) 0.234
Stomatitis 16 (21.6) 0 16 (21.6) 18 (17.6) 0 18 (17.6) 0.510
Hearing loss 1 (1.4) 0 1 (1.4) 0 0 0 0.420
Total any 28 (37.8) 1 (1.4) 29 (39.2) 40 (39.2) 6 (5.9) 46 (45.1) 0.434
Table 6  Late toxicities in 
patients treated with 2D-CRT 
versus IMRT
2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy
a Grade 2–4 toxicities
Late toxicity 2D-CRT (n = 74, %) IMRT (n = 102, %) P
Xerostomiaa 39 (52.7) 35 (34.3) 0.015
Hearing  lossa 30 (40.5) 23 (22.5) 0.010
Skin dystrophy 29 (39.2) 30 (29.4) 0.175
Neck fibrosis 25 (33.8) 22 (21.6) 0.071
Trismus 11 (14.9) 8 (7.8) 0.138
Radiation encephalopathy 6 (8.1) 4 (3.9) 0.236
Cranial nerve palsy 7 (9.5) 4 (3.9) 0.134
Growth retardation 3 (4.1) 2 (2.0) 0.409
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that likely existed at first treatment required early systemic 
treatment. Two prospective multicentre studies, NPC-91-
GPOH (Mertens et al. 2005) and NPC-2003-GPOH/DCOG 
(Buehrlen et  al. 2012), demonstrated favourable results 
for multimodal treatment (neoadjuvant chemotherapy, and 
radiotherapy followed by interferon-β) in patients with pae-
diatric and adolescent NPC. After a median follow-up time 
of 30 months and 48 months, the overall survival and event-
free survival rates were 95–97% and 91–92.4%, respec-
tively. These promising outcomes indicate that interferon-β 
may provide a survival benefit in patients with paediatric 
NPC. However, further studies are needed to investigate the 
most effective chemotherapy regimens and their optimal 
timing with IMRT.
With better outcomes and longer survival, the preven-
tion of radiation-induced complications becomes more 
important, and several studies have demonstrated quality 
of life advantages with IMRT in children with NPC (Tao 
et  al. 2013; Guo et  al. 2015). Laskar et  al. (2008) com-
pared 2D-CRT with IMRT in 36 cases of paediatric and 
adolescent NPC. A significant reduction in acute Grade 3 
toxicities of the skin, mucous membrane, and pharynx was 
noted with the use of IMRT despite similar survival rates 
between the two groups. Moreover, the median time to the 
development of Grade 2 toxicities, including skin toxicity 
and mucositis, was delayed with IMRT. Tao et  al. (2013) 
assigned 34 children with non-disseminated NPC to evalu-
ate the long-term outcome and late toxicities with simul-
taneous integrated boost-intensity-modulated radiotherapy 
(SIB-IMRT). Grades 1–2 xerostomia and ototoxicity were 
the most common late toxicities. Only two patients (8.3%) 
developed grade 3 ototoxicity, and no patients developed 
grade 4 toxicities. The 5-year LRRFS, DMFS, DFS, and 
OS were 97.1, 88.2, 85.3, and 88.2%, respectively, which 
were comparable to the present data, confirming that an 
improved outcome and reduced toxicity could be achieved 
by IMRT in young NPC patients. Liu et al. (2014) studied 
158 childhood and adolescence NPC patients to compare 
IMRT with 2D-CRT. The result revealed that IMRT signifi-
cantly reduces trismus (27.3 vs. 3.6%, P = 0.03) and Grade 
2 xerostomia (37.9 vs. 10.3%, P = 0.02); however, no sur-
vival benefits are achieved with the use of IMRT. Similarly, 
our study reported a significant reduction of Grade 2–4 
xerostomia and hearing loss (P = 0.015, P = 0.010, respec-
tively) using IMRT.
As one of the most feared complications after radical 
radiotherapy, temporal lobe injury (TLI) can be devas-
tating for patients and accounts for approximately 65% 
of deaths from radiation-induced toxicities (Lee et  al. 
1992). The results from our study revealed a trend of 
higher incidence of radiation encephalopathy in 2D-CRT 
compared with IMRT (8.1 vs. 3.9%, P = 0.236), and one 
patient in the 2D-CRT group died of severe radiation 
encephalopathy in 88 months. Zhou et al. (2013) reported 
that IMRT significantly reduced the incidence of radia-
tion-induced TLI compared with the 2D-CRT (7.5 vs. 
10.8%, P = 0.048). Mao et  al. (2014) also observed less 
extensive and milder temporal lobe necrosis (TLN) in 
the IMRT group. We hypothesize that the improvement 
observed with IMRT is largely due to the technical advan-
tages of IMRT. Compared with opposed lateral fields in 
conventional 2D radiation therapy, modern IMRT uti-
lizes multiple small segments of beams (pencil beams), 
and the intensities of the neighbouring pencil beams vary. 
Collectively, beams composed of segments with different 
intensities produce dose distributions that conform to the 
required shape of the targets. Furthermore, the popular 
adopted simultaneous integrated boost (SIB) dosing regi-
men has the advantage of providing a more conformal 
dose distribution, thereby facilitating enhanced sparing 
of critical normal structures (Chen et al. 2005).
To the best of our knowledge, the present analysis is the 
only study reporting significant advantages of IMRT com-
pared with 2D-CRT regarding the survival rate and late 
treatment-related toxicities in children and adolescent NPC. 
Our study, however, has several limitations. The main limi-
tation is its retrospective nature and the sample size. The 
establishment of treatment guidelines for paediatric NPC is 
needed through multi-centre collaboration on randomized 
controlled trials. Furthermore, radiation-induced toxicities 
may develop over time, especially for young patients, and a 
longer follow-up period is desirable to determine the exact 
incidences of these complications and the actual superior-
ity of IMRT in reducing late toxicities (e.g. endocrinopa-
thies, cranial nerve palsy, and second neoplasms).
In conclusion, IMRT provides better locoregional 
relapse-free survival and overall survival, especially in 
late-stage children and adolescent NPC patients and is 
associated with a lower incidence of Grade 2–4 xeros-
tomia and hearing loss compared with 2D-CRT. Distant 
metastasis remains a challenge in the treatment of chil-
dren and adolescent NPC.
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